Compile Data Set for Download or QSAR
Report error Found 978 Enz. Inhib. hit(s) with all data for entry = 11905
TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658888(US20240092758, Example 5)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658890(US20240092758, Example 7)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658891(US20240092758, Example 8)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658892(US20240092758, Example 9)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658894(US20240092758, Example 11)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658896(US20240092758, Example 13)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658897(US20240092758, Example 14)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658898(US20240092758, Example 15)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658901(US20240092758, Example 18)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658902(US20240092758, Example 19)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658902(US20240092758, Example 19)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658903(US20240092758, Example 20)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658903(US20240092758, Example 20)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658904(US20240092758, Example 21)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658904(US20240092758, Example 21)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658905(US20240092758, Example 22)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658907(US20240092758, Example 24)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658910(US20240092758, Example 27)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658910(US20240092758, Example 27)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658916(US20240092758, Example 33)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658916(US20240092758, Example 33)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658917(US20240092758, Example 34)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658917(US20240092758, Example 34)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658918(US20240092758, Example 35)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658918(US20240092758, Example 35)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658919(US20240092758, Example 36)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658921(US20240092758, Example 38)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658923(US20240092758, Example 40)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658923(US20240092758, Example 40)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658924(US20240092758, Example 41)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658925(US20240092758, Example 42)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658925(US20240092758, Example 42)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658926(US20240092758, Example 43)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658928(US20240092758, Example 45)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658933(US20240092758, Example 50)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658933(US20240092758, Example 50)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658934(US20240092758, Example 51)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658934(US20240092758, Example 51)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658935(US20240092758, Example 52)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658935(US20240092758, Example 52)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658936(US20240092758, Example 53)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658936(US20240092758, Example 53)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658937(US20240092758, Example 54)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658937(US20240092758, Example 54)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658938(US20240092758, Example 55)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658938(US20240092758, Example 55)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658939(US20240092758, Example 56)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658939(US20240092758, Example 56)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658941(US20240092758, Example 58)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM658941(US20240092758, Example 58)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 978 total ) | Next | Last >>
Jump to: